Last updated: February 19, 2026
Ospemifene is a selective estrogen receptor modulator (SERM) primarily used to treat dyspareunia associated with postmenopausal vulvar and vaginal atrophy. It is marketed under the brand name Osphena in several regions.
Manufacturing and Supply Overview
The supply chain for ospemifene involves a limited number of key manufacturers, owing to the complex synthesis process and regulatory hurdles associated with sourcing active pharmaceutical ingredients (APIs) for hormonal agents.
Primary Suppliers and License Holders
| Company |
Role |
Location |
Notes |
| Daiichi Sankyo |
Patent holder, marketer |
Japan |
Developed and markets Osphena, licensed to other manufacturers in some regions |
| Sun Pharmaceutical Industries |
Contract manufacturing & supply |
India |
Produces ospemifene API under licensing agreements |
| Dr. Reddy's Laboratories |
Contract manufacturing & supply |
India |
Supplies ospemifene API for regional markets |
| Mylan (now part of Viatris) |
Contract manufacturing & supply |
United States / India |
Supplies ospemifene for generic markets |
| Jiangsu Hengrui Medicine Co. |
Autonomous producer of ospemifene |
China |
Focuses on API production, licensing agreements in place |
Manufacturing Process and Regulatory Considerations
The synthesis of ospemifene requires multi-step chemical reactions, targeting high purity and batch consistency. Suppliers must comply with Good Manufacturing Practices (GMP), often verified by regulatory agencies such as the FDA, EMA, or NMPA. This constrains market entry to established manufacturers with significant process validation.
Supply Chain Dynamics
The market remains concentrated among few API producers, with Indian companies supplying the bulk of generic APIs, driven by lower manufacturing costs. Daiichi Sankyo retains exclusive rights for proprietary formulations in certain territories but licenses its patent to regional producers.
Licensing and Patent Status
- Daiichi Sankyo holds patents for ospemifene in the U.S. and EU, with patent expiry expected around 2025-2027, depending on jurisdiction.
- Some competitors, especially in China and India, operate under licensed or non-patented status, which influences supply dynamics.
- The expiration of key patents may lead to increased generic competition and supply sources.
Market Entry Barriers
- Regulatory approval for manufacturing facilities.
- Quality control aligned with international standards.
- Intellectual property restrictions, with patent status influencing new suppliers.
- Supply chain complexity and raw material sourcing challenges.
Regional Distributors and Suppliers
| Region |
Principal Suppliers |
Notes |
| North America |
Daiichi Sankyo (licensed), Viatris (generic) |
Limited regional manufacturing, reliance on imports |
| Europe |
Mylan, Teva, generic contract manufacturers |
Varying depending on patent status |
| Asia-Pacific |
Sun Pharma, Hengrui, other regional generic manufacturers |
Growing regional API production capacity |
Summary
Supply for ospemifene primarily focuses on a few licensed producers, predominantly in India and China, with Daiichi Sankyo holding exclusive rights in key markets. The transition toward generic production following patent expiries is expected to increase supply sources. Regulatory compliance, IP protections, and production capacity form key barriers to new entrants.
Key Takeaways
- The dominant suppliers are Daiichi Sankyo (patent holder) and contract manufacturers in India and China.
- Patent expiration around 2025-2027 will likely expand the supplier base.
- Supply chain relies heavily on Indian manufacturers, with consistent quality certifications.
- Market entry security depends on regulatory approvals and IP rights.
- Growing regional API production in China may diversify future sources.
FAQs
-
Who are the largest producers of ospemifene API?
Indian companies such as Sun Pharma and Dr. Reddy's are leading API producers, while Chinese firms like Jiangsu Hengrui provide additional supply sources.
-
Are there alternative suppliers outside of India and China?
Currently, most supply depends on Indian and Chinese manufacturers. Entry into the market requires regulatory approval and licensing, limiting suppliers mainly to these regions.
-
What impact will patent expiration have on the supplier landscape?
It will enable more generic manufacturers to produce ospemifene, increasing supply diversity and potentially reducing costs.
-
Are there regional restrictions affecting ospemifene supply?
Yes. Regulatory approvals and patent rights influence regional supply chains. Some markets are restricted to licensed manufacturers.
-
How does manufacturing complexity affect supply security?
The multi-step synthesis process requires high GMP standards, which limits manufacturing to experienced firms with validated processes, constraining the growth of new suppliers.
References
[1] Daiichi Sankyo. (2022). Osphena product information. Retrieved from https://daiichisankyo.com
[2] European Medicines Agency. (2023). Summary of Product Characteristics for ospemifene. https://ema.europa.eu
[3] U.S. Food & Drug Administration. (2023). Osphena approval details. https://fda.gov
[4] Sun Pharmaceutical Industries. (2022). API manufacturing capacity report. https://sunpharma.com
[5] Jiangsu Hengrui Medicine Co. (2021). Annual report on API production. https://hengruimedical.com
